MEA spokesperson Anurag Srivastava said the supply of vaccines to countries will continue in the coming weeks and months in a phased manner but it will be ensured that domestic requirements for the national vaccination programme are kept in mind

The Food and Drug Administration said Thursday that it's allowing the additional option after reviewing new data from New York-based Pfizer and its German partner, BioNTech

Of the nine million people in Israel, a nation with universal healthcare, nearly half have received a first dose of the COVID-19 vaccine, and a third have received both doses since the rollout began on December 19. This made the country a prime location for a real-world study into the vaccine's ability to stem the pandemic, along with its advanced data capabilities. But even as the country's economy starts opening up, there's a long way to go before pre-pandemic normalcy sets in. Watch the video for more on how Israel achieved this feat and why it still has many challenges ahead. Also Read: COVID-19 illness risk fell 95.8% after both Pfizer vaccine doses, says Israel

The real-world study involved around 1.2 million people in Israel. Pfizer vaccine has also proved to be effective against B.1.1.7 variant, also known as the UK variant of coronavirus

Located in the city of Pune in Maharashtra, the SII is the world's largest vaccine manufacturer by volume

AstraZeneca's statement late in the day said the company was striving to increase productivity to deliver the promised 180 million doses

Stock Market Updates Today: Sectorally, except for IT and pharma index, all the other indices ended with decent gains. Private, PSU Bank and financial indices closed 3% higher today.

Stocks to watch today on February 24: Coal India, Pfizer, SBI Cards, Tata Power, NTPC, UPL among others are the top stocks to watch out for in Wednesday's trading session

Data analysed by Public Health England (PHE) showed the Pfizer provided high levels of protection against infection and symptomatic disease from a single dose

Pfizer has shipped around 40 million doses to locations across the United States so far and is on track to deliver 120 million doses of its two-dose regimen by the end of March, said John Young, Pfizer's chief business officer

Up to 4 million Australians are expected to be inoculated by March, with Morrison among a small group receiving the first round of the Pfizer-BioNTech vaccine

The vaccine was also 98% effective in preventing fever or breathing problems and 98.9% effective in preventing hospitalizations and death, the ministry said

New Zealand expects its nationwide rollout covering the country's population of 5 million will take a full year, while Australia aims to inoculate its 25 million citizens by October

Symptoms, as reported in clinical trials for the AstraZeneca shot, can include a high temperature or headache and are a normal sign that the body is generating an immune response

Phil Dormitzer, one of Pfizer's top viral vaccine scientists, said in an interview that he believes the current vaccine is highly likely to still protect against the concerning variant first discovered in South Africa

Biden will also encourage G-7 partners to make good on their pledges to COVAX, an initiative by the World Health Organization to improve access to vaccines, according to a senior administration official

PM Modi calls for lower import dependence as petrol prices touch Rs 100; COVID-19 vaccine likely to be available in open market after 'prime targets' covered, says Randeep Guleria, AIIMS Director; South African variant could significantly reduce vaccine protection, says Pfizer. Watch this and more news on News Blast.

The revised standard operating procedures (SOPs) for international arrivals issued by the Health Ministry on February 17 comes in the wake of mutant variants of Covid-19 virus driving the pandemic in these countries

South African variant could significantly reduce vaccine protection, says Pfizer A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer-BioNTech vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday. Companies are making investments and talking to regulators about developing an updated version of their mRNA vaccine or a booster shot, if needed. COV...

Pfizer and BioNTech said they were doing similar lab work to understand whether their vaccine is effective against another variant first found in Brazil